[Vaccine against bilharziasis. Strategies and perspectives].
Due to the determination of immunity acquisition mechanisms, a number of studies on experimental models and human populations has made it possible to devise a strategy of vaccination against schistosomiasis, a major worldwide parasitic disease affecting 200 million people. A schistosomial protein, identified as glutathione-S-transferase (SM28GST) has been cloned and expressed in various vectors. Immunization with the recumbent protein results in a significant reduction of the parasitic load, while the fertility of schistosoma and the viability of its eggs are markedly inhibited. Recent experiments performed in primates and bovines have shown that a more than 90% inhibition of the schistosoma's transmission potential can be induced by this vaccine. The important role played by IgA antibodies in the inhibition of the parasite's fertility has led to the development of an oral immunization strategy. In view of the results obtained, the availability, in the near future, of a vaccine protecting human beings against this scourge can be considered realistic.
Capron
A
A
Centre d'immunologie et de biologie parasitaire, Unité mixte INSERM U167, CNRS 624, Institut Pasteur, Lille.
D000818:Animals; D005982:Glutathione Transferase / Q000627:therapeutic use; D006801:Humans; D012547:Schistosoma / Q000276:immunology; D012552:Schistosomiasis / Q000276:immunology / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use*
D014614:Vaccines, Synthetic; D005982:Glutathione Transferase
Un vaccin contre les bilharzioses. Stratégies et perspectives.